Celldex Therapeutics Cash Flow Statement
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics free cash flow
In fiscal 2025, Celldex Therapeutics generated -$210.9 million of operating cash flow and spent $2.7 million on capital expenditures. That left free cash flow of -$213.7 million, a free-cash-flow margin of -13829.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M | -59.78M | -50.88M | -151.18M | -93.03M | -128.53M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.38M | 3.18M | 3.01M | 2.90M | 3.07M | 3.93M | 4.86M | 3.58M | 4.41M | 3.10M |
| Stock-Based Compensation | 36.22M | 34.24M | 23.89M | 15.61M | 8.95M | 3.92M | 4.55M | 8.08M | 12.31M | 15.32M |
| Change in Working Capital | 5.35M | -1.71M | 7.56M | -3.90M | 817.00K | -299.00K | -4.68M | -15.37M | -13.00M | -7.88M |
| Operating Cash Flow | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M | -40.40M | -46.41M | -75.23M | -99.93M | -113.04M |
| Capital Expenditures | -2.71M | -1.92M | -1.82M | -1.83M | -1.25M | -1.55M | -731.00K | -813.00K | -1.79M | -2.75M |
| Investing Cash Flow | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M | -98.22M | 17.08M | 29.82M | 46.47M | 68.91M |
| Debt Issued | — | — | — | — | — | 2.96M | — | — | — | — |
| Debt Repaid | — | — | — | — | — | -2.96M | — | — | — | — |
| Financing Cash Flow | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M | 171.23M | 16.26M | 29.44M | 51.29M | 14.48M |
| Net Change in Cash | 515.00K | -6.46M | 5.38M | -9.71M | -4.69M | 32.60M | -13.08M | -15.98M | -2.17M | -29.65M |
| Free Cash Flow | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M | -41.96M | -47.15M | -76.05M | -101.72M | -115.79M |
This table shows 10 annual periods of Celldex Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a cash flow statement?